CORR Insights®: Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
Author:
Affiliation:
1. Associate Professor of Orthopaedic Surgery, Department of Orthopaedic Surgery, The Johns Hopkins University, Baltimore, MD, USA
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Orthopedics and Sports Medicine,General Medicine,Surgery
Reference11 articles.
1. Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma;Chow;Cancer,2020
2. A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet‐derived growth factor receptor‐α or ‐β: an Italian Sarcoma Group study;Grignani;Cancer,2011
3. IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors;Molenaar;Clin Cancer Res,2018
4. PARP-1 inhibition sensitizes temozolomide- treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency;Montaldi;Oncol Rep,2020
5. Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets;Onishi;Sarcoma,2011
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3